close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.3335 +0.0050 (+1.52%)
Streaming Delayed Price Updated: 12:13 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IGC Pharma, Inc. Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
420 with CNW — FDA Seeks More Data in Fight Against Delta-8 THC Products
Via Investor Brand Network
Topics Cannabis Derivatives
420 with CNW — FDA Seeks More Data in Fight Against Delta-8 THC Products
Via CannabisNewsWire
Topics Cannabis Derivatives
Research Links Diets High in Fat to Chronic Pain
Via Investor Brand Network
420 with CNW — DOJ Requests Additional Time in Cannabis Consumption Sites Case
Via Investor Brand Network
Topics Cannabis Government Law Enforcement
420 with CNW — DOJ Requests Additional Time in Cannabis Consumption Sites Case
Via CannabisNewsWire
Topics Cannabis Government Law Enforcement
420 with CNW — Colorado Regulators Allow Medical Cannabis to Be Recategorized as Recreational Marijuana
Via CannabisNewsWire
Topics Cannabis
420 with CNW — Colorado Regulators Allow Medical Cannabis to Be Recategorized as Recreational Marijuana
Via Investor Brand Network
Topics Cannabis
Existing Drug May Alleviate Side Effects of Cancer Treatment
Via Investor Brand Network
420 with CNW — New Study Finds Medical Cannabis Legalization Reduces Use of Opioids by Cancer Patients
Via Investor Brand Network
Topics Cannabis
420 with CNW — New Study Finds Medical Cannabis Legalization Reduces Use of Opioids by Cancer Patients
Via CannabisNewsWire
Topics Cannabis
CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Applauds Milestone Development for Medical Cannabis Industry
Via Investor Brand Network
Topics Cannabis
CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Applauds Milestone Development for Medical Cannabis Industry
Via CannabisNewsWire
Topics Cannabis
BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Commences Trial Evaluating IGC-AD1 for the Treatment of Alzheimer’s-Related Symptoms
Via Investor Brand Network
BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Present at RHK 2022 Disruptive Growth Conference
Via Investor Brand Network
News headline image
IGC Starts Phase 2 Clinical Trials Of THC Based Drug Candidate For The Treatment Of Agitation In Dementia From Alzheimer's Disease ↗
India Globalization Capital, Inc. (AMEX:IGC) has begun “A phase 2, multi-center, double-blind, randomized, placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants... 
Via Benzinga
News headline image
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease
From India Globalization Capital, Inc.
Via Business Wire
InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Numbers for Q2
Via Investor Brand Network
Topics Intellectual Property
India Globalization Capital Inc. (NYSE American: IGC) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
News headline image
IGC Q2 2023 Revenue Grows 261%, THC Based Drug For Alzheimer's Entering Phase 2 Trials ↗
India Globalization Capital, Inc. (AMEX:IGC) reported its second fiscal quarter 2023 financial results, revealing revenue of $202,000, a 261% increase compared to $56,000 in the same quarter of 2022. 
Via Benzinga
News headline image
IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022
From India Globalization Capital, Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning. 
Via InvestorPlace
News headline image
IGC Announces Issuance Of Second Patent For The Treatment Of Alzheimer's Using THC ↗
India Globalization Capital, Inc. (AMEX:IGC) announced that the United States Patent and Trademark Office issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme... 
Via Benzinga
News headline image
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
From India Globalization Capital, Inc.
Via Business Wire
News headline image
IGC Announces Results of its 2022 Annual Stockholders Meeting
From India Globalization Capital, Inc.
Via Business Wire
News headline image
IGC Stock Slightly Up On Q1 2023 Revenue Growth Of 175%, What About Gross Profit? ↗
India Globalization Capital, Inc. (AMEX:IGC) revenue in Q1 2023 was approximately $212,000 an increase of 175% compared to $77,000 in the same quarter of 2022. 
Via Benzinga
News headline image
IGC Reports Financial Results for the Quarter Ended June 30, 2022
From India Globalization Capital, Inc.
Via Business Wire
News headline image
IGC Revenue Drops 55.8% In Fiscal 2022, What About Gross Profit? ↗
India Globalization Capital, Inc. (AMEX:IGC) revenue in fiscal 2022 was $397,000, a 55.8% decrease compared to $898,000 in fiscal 2021. 
Via Benzinga
News headline image
IGC Reports Financial Results for Fiscal Year Ended March 31, 2022
From India Globalization Capital, Inc.
Via Business Wire
News headline image
IGC Acquires Exclusive Rights For A Potential Alzheimer's Drug Development Candidate ↗
One of subsidiaries of India Globalization Capital, Inc. (NYSE: IGC) reached an intellectual property license agreement for a potential Alzheimer’s drug development candidate. 
Via Benzinga
News headline image
IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate
From India Globalization Capital, Inc.
Via Business Wire
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today